Blood samples for pharmacokinetic evaluation were taken at each study visit, while exploratory biomarkers were collected at weeks 1, 5, 8, and 12, as well as at end-of-treatment and follow-up [1]
These sustained results were achieved with once-weekly injection and lifestyle support, establishing semaglutide as a clinically validated weight management option
Manufacturing, branded labeling, fulfillment, and compliance run on our side
Richter RP, Ashtekar AR, Zheng L, Pretorius D, Kaushlendra T, Sanderson RD, Gaggar A, Richter JR
I cambiamenti medi nel peso corporeo rispetto allinizio del trial erano simili in tutti i sottogruppi di partecipanti, compresi quelli con e senza prediabete allinizio del trial (Figura S5 e S6)
Ans: In some cases, yes